Arabi Seyyed Mostafa, Bahari Hossein, Hamidipor Sina, Bahrami Leila Sadat, Feizy Zahra, Nematy Mohsen, Kesharwani Prashant, Sahebkar Amirhossein
Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Phytother Res. 2022 Dec;36(12):4361-4370. doi: 10.1002/ptr.7642. Epub 2022 Oct 7.
In the past decade, the effect of curcumin or turmeric supplementation on many aspects of health status in different populations has been evaluated. In the present study, a systematic review and meta-analysis were conducted to estimate the effect of curcumin administration on inflammatory markers in hemodialysis (HD) patients. A systematic search was performed in MEDLINE, EMBASE, Scopus, and Clarivate Analytics Web of Science databases from 1997 until June2022 for terms related to curcumin/turmeric and hemodialysis (HD). Randomized, double-blind/single-blind studies examining the effects of curcumin/turmeric on the inflammation of HD participants older than 18 years were considered eligible for inclusion. Data were pooled using the weighted mean difference (WMD) and 95% CI as the summary statistic, considering a random-effects analysis model. The data that were pooled from nine studies with 472 patients indicated that curcumin-containing supplement had significant effect on serum C-reactive protein (CRP) levels (WMD = -3.3 mg/L; 95% CI: -5.4 to -1.3; p < 0.001, I = 76.7%, 8 studies, 467 participants), and interlukine-6 (IL-6) levels (SMD: -0.4; 95% CI: -0.8 to -0.07; p = 0.02, I = 31.6%, 3 studies, 153 participants) compared control group. Although curcumin intervention could not change tumor neurosis factor-α (TNF-α) concentration (SMD = -0.3; 95% CI: -0.7 to 0.04; p = 0.08, I = 25.3%, 3 studies, 153 participants), when compared with the placebo group. Our study's main limitations were small number of studies, overall high risk of bias in the included trials, and high heterogeneity in some results. The present meta-analysis suggested that intervention with curcumin-containing supplements was associated with a significant reduction in serum hs-CRP and IL-6 concentrations in HD patients. The curcumin intervention in the reduction of hs-CRP levels was greater than the minimal clinically important difference (MCID) for CRP (0.5 mg/L), which can be helpful in physicians' clinical decisions.
在过去十年中，已对姜黄素或姜黄补充剂对不同人群健康状况诸多方面的影响进行了评估。在本研究中，进行了一项系统评价和荟萃分析，以评估给予姜黄素对血液透析（HD）患者炎症标志物的影响。从1997年至2022年6月，在MEDLINE、EMBASE、Scopus和科睿唯安科学网数据库中进行了系统检索，查找与姜黄素/姜黄和血液透析（HD）相关的术语。考察姜黄素/姜黄对18岁以上HD参与者炎症影响的随机、双盲/单盲研究被认为符合纳入条件。使用加权平均差（WMD）和95%置信区间（CI）作为汇总统计量合并数据，采用随机效应分析模型。从9项研究的472例患者中汇总的数据表明，含姜黄素补充剂对血清C反应蛋白（CRP）水平有显著影响（WMD = -3.3 mg/L；95% CI：-5. _4至-1.3；p < 0.001，I² = 76.7%，8项研究，467名参与者），以及对白细胞介素-6（IL-6）水平有显著影响（标准化均数差：-0.4；95% CI：-0.8至-0.07；p = 0.02，I² = 31.6%，3项研究，153名参与者），与对照组相比。尽管与安慰剂组相比，姜黄素干预不能改变肿瘤坏死因子-α（TNF-α）浓度（标准化均数差 = -0.3；95% CI：-0.7至0.04；p = 0.08，I² = 25.3%，3项研究，153名参与者）。本研究的主要局限性是研究数量少、纳入试验总体偏倚风险高以及一些结果的异质性高。本荟萃分析表明，含姜黄素补充剂的干预与HD患者血清hs-CRP和IL-6浓度显著降低相关。姜黄素干预降低hs-CRP水平的幅度大于CRP的最小临床重要差异（MCID）（0.5 mg/L），这可能有助于医生的临床决策。
